Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meiji Seika Pharma Co., Ltd

http://www.meiji-seika-pharma.co.jp/english/

Latest From Meiji Seika Pharma Co., Ltd

Dong-A ST Achieves Therapeutic Equivalence With Stelara Biosimilar

Dong-A has achieved therapeutic equivalence for its ustekinumab biosimilar candidate DMB-3115 in clinical studies and now plans to file for marketing authorization for the product in both the EU and US.

Clinical Trials Advertising, Marketing & Sales

FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022

Pink Sheet infographic breaks down the trends and surprises in 2022 approvals. Cancer therapies and non-malignant hematology exceeded the average use of expedited review programs but were weighted to orphan diseases, while dermatology saw first-in-class approvals for big markets.

Pink Sheet Perspectives Approvals

Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System

The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.

Distribution Pricing Debate

Japan’s Drug Distribution Crisis: Pharma Urges Govt To Reform Pricing System

The impact of drug shortages in Japan, including of essential products, is being considered as part of government-level discussions to consider the appropriateness of the current reimbursement pricing system. Amid rising production costs and wider global challenges, some experts in the industry are now asking for price increases.

Japan Distribution
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Chemo-Sero Therapeutic Research Institute of Japan
    • Meiji Holdings
    • Meiji Seika Kaisha
    • KM Biologics Co., Ltd.
    • Kaketsuken
    • Romeck Pharma, LLC
    • Meiji Pharma USA Inc.
UsernamePublicRestriction

Register